Zerlasiran was found to be well tolerated and no significant safety concerns were observed. Credit: Good dreams - Studio via ...

At AHA, Phase 2 results from Eli Lilly and Silence Therapeutics are seen as signs of a "major new path" of cardiovascular ...

While having HDL levels above 60 mgdL is often seen as a sign of good health it’s not a standalone indicator Read ahead to ...

A little more than a month after AstraZeneca jumped into the fray with the purchase of a rival heart drug candidate, Eli ...

Two drugs targeting lipoprotein(a) are showing promise in cardiovascular disease, Phase 2 data presented at the American ...

The highest dose of an experimental pill developed by Eli Lilly dramatically lowered an inherited form of high cholesterol in ...

On Monday, Eli Lilly And Co (NYSE:LLY) announced Phase 2 results for muvalaplin, an investigational once-daily, orally ...

A clinical trial testing muvalaplin, a novel oral medication, was able to safely and effectively lower high levels of ...

Eli Lilly said the treatment, a once-daily pill called muvalaplin, showed reductions in Lp (a) levels compared to placebo. Injectables are currently in Phase 3 development, but "these are the first ...

Data reveal a strong association between non–high-density lipoprotein (non-HDL) cholesterol to HDL cholesterol ratio and ...

Eli Lilly (LLY) and Company announced “positive” Phase 2 results for muvalaplin, an investigational once-daily, orally administered selective inhibitor of lipoprotein(a), or Lp(a), a genetically ...

"AHA 2024: Muvalaplin shows promising Phase II results for elevated serum lipoprotein (a)" was originally created and ...